Third Harmonic Bio, Inc. (THRD)
(Delayed Data from NSDQ)
$13.65 USD
+0.21 (1.56%)
Updated May 30, 2024 04:00 PM ET
After-Market: $13.66 +0.01 (0.07%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
THRD 13.65 +0.21(1.56%)
Will THRD be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for THRD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for THRD
Biogen (BIIB) Partner Begins Filing for Leqembi SC Autoinjector
AbbVie (ABBV) Boosts Neuropsychiatric Portfolio With New Deal
THRD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Theravance (TBPH) Q1 Earnings Top, Revenues Match Estimates
Intellia's (NTLA) Q1 Earnings & Revenues Beat Estimates
Mirum's (MIRM) Q1 Earnings & Revenues Fall Shy of Estimates
Other News for THRD
Third Harmonic Bio to Participate in the Jefferies Global Healthcare Conference
Third Harmonic Bio, Inc.: Positive Outlook on THB335’s Clinical Advancements and Strategic Developments
Third Harmonic Bio GAAP EPS of -$0.23
THRD Stock Earnings: Third Harmonic Bio Beats EPS for Q1 2024
Third Harmonic Bio Announces First Quarter 2024 Financial Results and Provides Business Update